{"product_id":"fruquintinib-for-colorectal-cancer-what-the-latest-evidence-shows-about-survival-and-side-effects","title":"Fruquintinib for Colorectal Cancer: What the Latest Evidence Shows About Survival and Side Effects","description":"\u003cp\u003eThis meta-analysis of 11 Chinese studies involving 2,367 patients found that fruquintinib, an oral targeted cancer drug, significantly improved both overall survival and progression-free survival in people with colorectal cancer, without raising the overall risk of adverse events or serious adverse events. The drug reduced the risk of death by about 31% and the risk of cancer progression by about 56%. However, the analysis flagged a possible but unconfirmed link to high blood pressure, and the authors stress that larger, more rigorous trials are still needed to confirm these findings.\u003c\/p\u003e\n\n\u003ch1\u003eFruquintinib for Colorectal Cancer: What the Latest Evidence Shows About Survival and Side Effects\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters: Colorectal Cancer and the Need for New Treatments\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#about-drug\"\u003eWhat Is Fruquintinib?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted This Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#studies\"\u003eThe 11 Studies Included: A Closer Look\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#os\"\u003eSurvival Results: Overall Survival\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#pfs\"\u003eSurvival Results: Progression-Free Survival\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#safety\"\u003eSide Effects: Any Adverse Events and Serious Adverse Events\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#specific-side-effects\"\u003eSpecific Side Effects: Hypertension and Fatigue\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#sensitivity\"\u003eChecking the Strength of the Results (Sensitivity Analysis and Publication Bias)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#how-acts\"\u003eUnderstanding How Fruquintinib Works Inside the Body\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat These Findings Mean for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What the Research Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations from the Researchers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFruquintinib reduced death risk by about 31% and progression risk by about 56% in an analysis of 11 Chinese colorectal cancer studies.\u003c\/li\u003e\n\u003cli\u003eNo significant increase in overall or serious side effects was seen, but high blood pressure remained a possible unconfirmed concern.\u003c\/li\u003e\n\u003cli\u003eAll 11 studies were conducted in China, mostly in advanced or previously treated colorectal cancer patients.\u003c\/li\u003e\n\u003cli\u003eHypertension monitoring, including weekly checks, is advised during fruquintinib treatment, with treatment pauses or dose changes for severe cases.\u003c\/li\u003e\n\u003cli\u003eLarger, multicenter, double-blind trials are needed to confirm fruquintinib's efficacy and safety findings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters: Colorectal Cancer and the Need for New Treatments\u003c\/h2\u003e\n\n\u003cp\u003eColorectal cancer (cancer of the colon or rectum) is one of the most common causes of illness and death worldwide. In 2020, the World Health Organization (WHO) reported more than 1.93 million new cases and 935,000 deaths from the disease. That makes colorectal cancer the third most common cancer globally and the second leading cause of cancer-related deaths.\u003c\/p\u003e\n\n\u003cp\u003eIn Asia, the number of colorectal cancer cases has been rising steadily, particularly in China. Researchers attribute this increase to changes in lifestyle and diet, and the disease has become a major public health concern there.\u003c\/p\u003e\n\n\u003cp\u003eBetter early diagnosis and improved surgical techniques have brightened the outlook for many colorectal cancer patients. Yet treating metastatic colorectal cancer (mCRC, meaning cancer that has spread beyond the colon or rectum to other parts of the body) remains a major challenge.\u003c\/p\u003e\n\n\u003cp\u003eStandard treatment for advanced disease usually includes chemotherapy regimens such as FOLFOX or FOLFIRI, often combined with targeted therapies like anti-EGFR or anti-VEGF monoclonal antibodies. However, drug resistance is a serious problem. When tumors stop responding, the later-line treatment options that remain have only limited effectiveness. Developing new targeted therapies to improve survival for people with metastatic colorectal cancer has therefore become a central focus of clinical research.\u003c\/p\u003e\n\n\u003ch2 id=\"about-drug\"\u003eWhat Is Fruquintinib?\u003c\/h2\u003e\n\n\u003cp\u003eFruquintinib is an oral (taken by mouth), selective VEGFR-1\/2\/3 tyrosine kinase inhibitor originally developed by Chinese scientists. Put more plainly, it is a daily pill that blocks specific proteins called vascular endothelial growth factor receptors (VEGFRs), which tumors use to build new blood vessels. By interfering with this VEGF signaling pathway, fruquintinib suppresses tumor angiogenesis (the growth of new blood vessels that feed a tumor) and exerts anti-tumor effects.\u003c\/p\u003e\n\n\u003cp\u003eCompared with multi-target inhibitors such as regorafenib (another oral targeted drug used in colorectal cancer), fruquintinib appears to be more selective for VEGFR. It inhibits other kinases (helper enzymes) such as PDGFR and FGFR much less strongly. This selectivity may reduce \"off-target\" toxicity, meaning fewer side effects caused by the drug acting on proteins it was not designed to hit.\u003c\/p\u003e\n\n\u003cp\u003eClinical research on fruquintinib began in 2014, and early trials showed that the drug had anti-tumor activity and was generally tolerable in patients with mCRC.\u003c\/p\u003e\n\n\u003cp\u003eA pivotal trial called FRESCO (study number NCT02314819) followed. This was a randomized, double-blind, placebo-controlled phase III trial — the gold-standard type of study for testing a new treatment. It confirmed fruquintinib's effectiveness as a third-line treatment (a treatment given after two earlier lines have stopped working) for mCRC. The study showed significant improvements in:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian overall survival\u003c\/strong\u003e (the time by which half of patients were still alive): 9.3 months with fruquintinib versus 6.6 months with placebo, a hazard ratio (HR) of 0.65.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedian progression-free survival\u003c\/strong\u003e (the time before the cancer grew or spread): 3.7 months versus 1.8 months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese results led to approval of fruquintinib for third-line mCRC treatment in China in 2018 and by the U.S. Food and Drug Administration (FDA) for global use in 2023.\u003c\/p\u003e\n\n\u003cp\u003eDespite these clear benefits, existing studies have limitations, including small sample sizes and single-arm or single-center designs. Safety data across studies also looked inconsistent and needed further validation. One earlier meta-analysis, by Yonatan and colleagues in 2024, looked at fruquintinib for refractory mCRC but included only three studies, lacked significant real-world data, and produced low-quality evidence.\u003c\/p\u003e\n\n\u003cp\u003eThis new study was designed to pull together all available evidence — both clinical trials and real-world data — to get a clearer picture of how well fruquintinib works and how safe it is for Chinese patients with colorectal cancer, mainly those with advanced or treatment-resistant disease.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted This Review\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers followed an internationally recognized standard for systematic reviews called the PRISMA 2020 guidelines. The review was registered in advance in a public registry called PROSPERO, under the number CRD420251002004. Registering a study plan in advance helps prevent selective reporting and makes the research process transparent.\u003c\/p\u003e\n\n\u003cp\u003eThe team performed a thorough search of four major medical databases — PubMed, Embase, Web of Science, and Cochrane — up to January 2025. They searched for any studies evaluating fruquintinib in colorectal cancer treatment.\u003c\/p\u003e\n\n\u003cp\u003eThey used a structured PICOS format, a standard framework for defining review questions:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eP (Population):\u003c\/strong\u003e Patients with colorectal cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eI (Intervention):\u003c\/strong\u003e Fruquintinib alone or in combination with other treatments.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eC (Comparator\/Control):\u003c\/strong\u003e Treatments that did not include fruquintinib.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eO (Outcomes):\u003c\/strong\u003e Overall survival (OS), progression-free survival (PFS), and adverse events.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eS (Study types):\u003c\/strong\u003e Randomized controlled trials (RCTs) and cohort studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThey excluded study protocols, unpublished studies, and non-original research such as meeting abstracts, corrections, and replies. They also excluded studies with inadequate data where survival or safety numbers could not be obtained directly or through statistical transformation.\u003c\/p\u003e\n\n\u003cp\u003eTwo authors independently extracted data from each study and resolved any disagreements through discussion. They collected details including: first author and year of publication, study duration, region, design, registration number, patient population, intervention, control treatment, sample size, age, gender, follow-up period, OS, PFS, and safety outcomes. They contacted corresponding authors to fill in any missing details.\u003c\/p\u003e\n\n\u003cp\u003eFor quality assessment, two authors independently evaluated each study using recognized tools:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRCTs\u003c\/strong\u003e were assessed using the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0, covering seven domains: randomization (random assignment to groups), allocation concealment (hiding which group a patient will be assigned to), blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential biases.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCohort studies\u003c\/strong\u003e (observational studies that follow groups over time) were rated using the Newcastle-Ottawa Scale (NOS). Studies scoring 7–9 points were considered high quality.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor statistical analysis, the team calculated hazard ratios (HR) with 95% confidence intervals (CI) for survival outcomes and odds ratios (OR) with 95% confidence intervals for categorical variables. They used a random-effects model, which assumes that true effects may vary between studies. Heterogeneity (the degree to which study results differ from each other) was assessed using the chi-squared test and the I² statistic. They defined substantial heterogeneity as a chi-squared P-value below 0.1 or an I² value above 50%.\u003c\/p\u003e\n\n\u003ch2 id=\"studies\"\u003eThe 11 Studies Included: A Closer Look\u003c\/h2\u003e\n\n\u003cp\u003eThe initial search identified 426 studies across the four databases: 69 from PubMed, 188 from Embase, 126 from Web of Science, and 43 from Cochrane. After removing duplicates, 338 titles and abstracts were screened. Ultimately, 11 studies (providing 13 comparison groups) met all the criteria and were included, involving a total of 2,367 patients.\u003c\/p\u003e\n\n\u003cp\u003eAll studies were conducted in China between 2017 and 2024. They included:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3 randomized controlled trials (RCTs)\u003c\/strong\u003e — the gold-standard experimental design.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e8 observational cohort studies\u003c\/strong\u003e — real-world evidence from patients treated in everyday clinical practice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe treatments varied considerably between studies, which the authors noted as an important caveat when interpreting pooled results. Four studies — Li 2018, Li 2020, Xu 2017, and Zhang 2022, with a total of 709 patients — evaluated fruquintinib as a \u003cstrong\u003emonotherapy\u003c\/strong\u003e (given alone), mainly as third-line or later-line treatment for mCRC.\u003c\/p\u003e\n\n\u003cp\u003eThe other seven studies evaluated \u003cstrong\u003ecombination therapy\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFruquintinib combined with PD-1 inhibitors (immunotherapy drugs) such as sintilimab — used in two studies (Sun 2021 and Nie 2022, with a total of 51 patients) for refractory microsatellite stable (MSS) mCRC, a subtype that tends not to respond well to immunotherapy alone.\u003c\/li\u003e\n  \u003cli\u003eFruquintinib combined with chemotherapy regimens such as raltitrexed\/S-1 — used in two study groups from Zhou 2024 (with a total of 120 patients, reported separately for males and females) in later-line treatment.\u003c\/li\u003e\n  \u003cli\u003eFruquintinib compared against other targeted agents like regorafenib or bevacizumab — used in mixed treatment lines across three studies (Deng 2023, Jin 2022, and Dai 2022, with a total of 308 patients).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatient populations were concentrated in advanced disease stages. Ten of the 11 studies enrolled only patients with stage IV (metastatic) colorectal cancer. Key subgroup analyses included patients with liver metastases (from Qin 2021, n = 287 total) and patients without liver metastases (from Qin 2021, n = 129). Nine of the 11 studies enrolled patients who had already received multiple lines of therapy (two or more prior treatment regimens), meaning this was a heavily pre-treated population.\u003c\/p\u003e\n\n\u003cp\u003eSample sizes varied widely. The largest were the FRESCO trial (Li 2018, n = 416 patients) and its subgroup analyses (Qin 2021, total n = 416). Moderate-sized cohorts included Zhang 2022 (n = 366) and Jin 2022 (n = 256). Smaller studies included Sun 2021 (n = 51) and Nie 2022 (n = 72).\u003c\/p\u003e\n\n\u003cp\u003eAll three RCTs were rated as having a low risk of bias across all seven quality domains assessed — a reassuring finding for the reliability of their results.\u003c\/p\u003e\n\n\u003ch2 id=\"os\"\u003eSurvival Results: Overall Survival\u003c\/h2\u003e\n\n\u003cp\u003eOverall survival (OS) — the length of time patients lived after starting treatment — was the most important outcome measured. Results for OS came from 10 comparison groups.\u003c\/p\u003e\n\n\u003cp\u003eThe meta-analysis showed that patients treated with fruquintinib lived significantly longer than those in the control groups. The hazard ratio was 0.69 (95% CI: 0.58, 0.81; P \u0026lt; 0.00001). In plain terms, this means that, at any given point during follow-up, patients taking fruquintinib had about a 31% lower risk of dying compared with patients not taking the drug.\u003c\/p\u003e\n\n\u003cp\u003eThere was no significant heterogeneity among the studies for this outcome (I² = 23%, P = 0.23). This means the survival benefit appeared consistently across different studies, strengthening confidence in the finding. The result was highly statistically significant, meaning the probability that it happened by chance is less than 0.001%.\u003c\/p\u003e\n\n\u003ch2 id=\"pfs\"\u003eSurvival Results: Progression-Free Survival\u003c\/h2\u003e\n\n\u003cp\u003eProgression-free survival (PFS) — the length of time patients lived without their cancer growing or spreading — was the second key outcome. PFS data also came from 10 comparison groups.\u003c\/p\u003e\n\n\u003cp\u003eThe analysis found that fruquintinib significantly prolonged PFS. The hazard ratio was 0.44 (95% CI: 0.30, 0.64; P \u0026lt; 0.0001). This translates to about a 56% lower risk of cancer progression or death at any given time point for patients in the fruquintinib group.\u003c\/p\u003e\n\n\u003cp\u003eHowever, unlike the OS analysis, there was notable heterogeneity among the studies for PFS (I² = 87%, P \u0026lt; 0.00001). \"Heterogeneity\" in statistical terms means the individual studies gave somewhat different results from each other, which can be a sign that underlying patient populations, treatment regimens, or methods of measuring progression varied between studies. The researchers therefore performed additional sensitivity analyses to investigate this variability (described below).\u003c\/p\u003e\n\n\u003ch2 id=\"safety\"\u003eSide Effects: Any Adverse Events and Serious Adverse Events\u003c\/h2\u003e\n\n\u003cp\u003eBecause fruquintinib is a relatively new drug, understanding its safety profile is just as important as proving its effectiveness. Two broad safety categories were analyzed.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAny adverse events\u003c\/strong\u003e were defined as any unwanted medical event of any grade (severity level) related to the study drug. \u003cstrong\u003eSerious adverse events\u003c\/strong\u003e were those of grade 3 or higher — the most severe category, typically requiring hospitalization or representing a life-threatening situation.\u003c\/p\u003e\n\n\u003cp\u003eFor \u003cstrong\u003eany adverse events\u003c\/strong\u003e, the analysis included four comparison groups. It revealed no significant difference in risk between the fruquintinib and control groups (OR: 0.71; 95% CI: 0.44, 1.15; P = 0.17). There was no heterogeneity among studies (I² = 0%, P = 0.47). In plain language, fruquintinib did not increase a patient's overall chance of experiencing any side effect compared to control treatments.\u003c\/p\u003e\n\n\u003cp\u003eFor \u003cstrong\u003eserious adverse events\u003c\/strong\u003e, the analysis also included four groups. Again, there was no significant difference in risk between fruquintinib and control groups (OR: 1.38; 95% CI: 0.73, 2.59; P = 0.32). This means patients on fruquintinib were not significantly more likely to experience severe, grade 3 or higher side effects. There was, however, notable heterogeneity (I² = 55%, P = 0.09), which the researchers investigated further in sensitivity analysis.\u003c\/p\u003e\n\n\u003ch2 id=\"specific-side-effects\"\u003eSpecific Side Effects: Hypertension and Fatigue\u003c\/h2\u003e\n\n\u003cp\u003eThe review also looked specifically at two side effects most commonly associated with this class of drug: high blood pressure (hypertension) and fatigue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHypertension\u003c\/strong\u003e results involved six comparison groups. The analysis showed no statistically significant increase in risk with fruquintinib (OR: 2.43; 95% CI: 0.97, 6.09; P = 0.06). It is important to note that the result was borderline — the P-value of 0.06 is just above the conventional threshold for significance of 0.05. The confidence interval is wide and crosses 1.0, meaning the analysis cannot rule out either no effect or a substantial increase in blood pressure risk. Heterogeneity was high (I² = 86%, P \u0026lt; 0.00001), suggesting the studies disagreed considerably with each other.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFatigue\u003c\/strong\u003e results comprised five groups. The analysis found no significant difference in fatigue risk between fruquintinib and control groups (OR: 0.77; 95% CI: 0.49, 1.23; P = 0.28), with no heterogeneity (I² = 0%, P = 0.82). If anything, the point estimate suggests a trend toward \u003cem\u003eless\u003c\/em\u003e fatigue with fruquintinib, though this did not reach statistical significance.\u003c\/p\u003e\n\n\u003ch2 id=\"sensitivity\"\u003eChecking the Strength of the Results (Sensitivity Analysis and Publication Bias)\u003c\/h2\u003e\n\n\u003cp\u003eWhen meta-analyses show significant heterogeneity, researchers perform sensitivity analyses to see whether any single study is driving the overall result. They do this by removing one study at a time and recalculating the pooled effect. If the result stays the same no matter which study is removed, the finding is considered robust. If removing one particular study changes the conclusion, that study is flagged as influential.\u003c\/p\u003e\n\n\u003cp\u003eHere, sensitivity analysis was performed on three outcomes: PFS, serious adverse events, and hypertension.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePFS:\u003c\/strong\u003e The analysis demonstrated consistent estimates when each study was excluded one by one. In other words, even though the individual studies varied (as reflected in the high I²), no single study was responsible for the overall survival benefit seen.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSerious adverse events:\u003c\/strong\u003e Results also remained consistent when each study was removed. However, removing the Li 2018 study (the FRESCO trial) reduced heterogeneity from 55% to 0%. This identified Li 2018 as the key source of the variability between studies when it came to serious side effects.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHypertension:\u003c\/strong\u003e This is where the sensitivity analysis produced an important finding. Removing the data from Sun 2021 shifted the result to a significant OR of 2.99 (95% CI: 1.07, 8.32). Similarly, removing Zhang 2022 shifted the result to a significant OR of 3.03 (95% CI: 1.22, 7.52). In both cases, the hypertension risk went from statistically non-significant to statistically significant once these studies were excluded.\u003c\/p\u003e\n\n\u003cp\u003eThis instability indicates that \u003cstrong\u003efruquintinib may indeed elevate the risk of hypertension\u003c\/strong\u003e, but that conclusion depends heavily on which studies are included. The presence of certain studies dilutes or masks the signal. The researchers also found that removing Li 2020 decreased hypertension heterogeneity from 86% to 52%, identifying Li 2020 as another major source of variability.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication bias\u003c\/strong\u003e is a separate concern in meta-analysis. It refers to the tendency for studies with positive results to be published while those with negative or null results languish unpublished, which can skew the literature. The authors used funnel plots and Egger's regression test to evaluate publication bias for OS and PFS. Both funnel plots were symmetrical, and the Egger test confirmed no significant publication bias (OS: P = 0.927; PFS: P = 0.179). This means there was no statistical evidence that important unpublished studies were missing from the analysis.\u003c\/p\u003e\n\n\u003ch2 id=\"how-acts\"\u003eUnderstanding How Fruquintinib Works Inside the Body\u003c\/h2\u003e\n\n\u003cp\u003eTo appreciate why fruquintinib matters for patients, it helps to understand its mechanism at a biological level. Fruquintinib is a selective inhibitor of VEGFR-1\/2\/3 tyrosine kinases. These are enzymes that sit on the surface of blood vessel cells and receive growth signals. When the VEGF signaling pathway is activated, it triggers a cascade of downstream signals inside cells — including the PI3K\/AKT and MAPK pathways — that drive endothelial cells (the cells lining blood vessels) to multiply, migrate, and form new blood vessels. Tumors depend on this process, called angiogenesis, to get the oxygen and nutrients they need to grow beyond a tiny size.\u003c\/p\u003e\n\n\u003cp\u003eFruquintinib works by competitively binding to the ATP-binding site of VEGFR-1\/2\/3. This blocks the receptors from activating, which stops autophosphorylation (a key activation step) and the downstream signaling that follows. The result is that endothelial cell proliferation, migration, and tumor angiogenesis are suppressed.\u003c\/p\u003e\n\n\u003cp\u003ePreclinical laboratory studies provide a more exact picture of fruquintinib's potency:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFruquintinib's IC50 (the concentration needed to inhibit 50% of the target's activity) for VEGFR-2 is 1.6 nM (nanomolar), which is lower than regorafenib's IC50 of 4.2 nM. A lower IC50 means the drug is more potent — it takes less fruquintinib to achieve the same degree of VEGFR-2 blockade.\u003c\/li\u003e\n  \u003cli\u003eFruquintinib shows much weaker effects on other kinases. Its IC50 for PDGFR-β is 100 nM, and for FGFR-1 it exceeds 1,000 nM — both far higher than the VEGFR values. This wide gap between VEGFR inhibition and PDGFR\/FGFR inhibition is the molecular basis for the drug's selectivity and its potentially cleaner safety profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCompared with bevacizumab, a widely used anti-angiogenic drug that targets only VEGF-A, fruquintinib has a potential advantage. Bevacizumab can become less effective due to \"bypass activation\" — tumors find alternate growth pathways involving other VEGF family members like VEGF-C and VEGF-D. By blocking VEGFR-1, VEGFR-2, and VEGFR-3, fruquintinib may overcome this limitation.\u003c\/p\u003e\n\n\u003cp\u003eCompared with regorafenib, which inhibits multiple kinases including RAF and KIT, fruquintinib's higher selectivity may reduce off-target toxicity. Multi-kinase inhibition is associated with side effects such as hand-foot syndrome (painful redness and peeling of the palms and soles). The lower fatigue risk observed in this meta-analysis supports the theoretical advantage of fruquintinib's selectivity.\u003c\/p\u003e\n\n\u003cp\u003eThe discussion also highlights promising laboratory research on combinations. In a colorectal cancer xenograft model (where human tumor cells are grown in mice), fruquintinib reduced tumor growth by 68%. When combined with PD-1 inhibitors, it enhanced infiltration of CD8+ T cells (a type of immune cell that attacks cancer) and reversed immunosuppression in the tumor environment. This suggests genuine potential for synergy with immunotherapy, an area of active investigation.\u003c\/p\u003e\n\n\u003cp\u003eThe FRESCO trials have now firmly established the clinical context. The FRESCO study (NCT02314819) demonstrated a median overall survival of 9.3 months versus 6.6 months (HR = 0.65) and median PFS of 3.7 versus 1.8 months. The global multicenter FRESCO-2 study then confirmed the drug's efficacy in a broader international population, showing a median overall survival of 7.4 versus 4.8 months (HR = 0.66). Importantly, consistent benefits were observed across subgroups, including patients who had previously been treated with anti-VEGF or anti-EGFR therapies. These FRESCO-2 results were a major factor in fruquintinib receiving FDA approval in 2023.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat These Findings Mean for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe headline conclusion of this meta-analysis is encouraging: fruquintinib significantly improved both overall survival and progression-free survival in colorectal cancer patients without increasing the overall incidence of adverse events or serious adverse events.\u003c\/p\u003e\n\n\u003cp\u003eThese findings align with earlier research, including the FRESCO trial series. They are also consistent with the Yonatan 2024 meta-analysis, which found survival and tumor-response benefits for fruquintinib in refractory mCRC. However, there is an important difference. Yonatan's analysis reported a higher incidence of grade 3 or greater adverse events, but it included only three clinical trials, which limited the strength of its safety conclusions.\u003c\/p\u003e\n\n\u003cp\u003eThis new review is substantially broader. By integrating six real-world cohort studies alongside the RCTs, the researchers significantly expanded the sample size and enhanced the ability to generalize the conclusions to everyday clinical practice. Real-world data matter because clinical trial patients are often healthier and more closely monitored than typical patients, so seeing similar benefits in routine practice is reassuring.\u003c\/p\u003e\n\n\u003cp\u003eThe one safety signal that deserves attention is hypertension. While the pooled result was not statistically significant (OR: 2.43; P = 0.06), the sensitivity analysis revealed instability: removing either Sun 2021 or Zhang 2022 flipped the result to significant. This finding aligns with the FRESCO study, which reported a 21.6% incidence of grade 3 (severe) hypertension — roughly 1 in 5 patients — among those taking fruquintinib.\u003c\/p\u003e\n\n\u003cp\u003eHow does fruquintinib raise blood pressure? The likely mechanism involves increased vascular resistance and reduced nitric oxide synthesis (nitric oxide is a molecule that helps blood vessels relax) caused by VEGFR inhibition. This is a known class effect of anti-angiogenic drugs.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What the Research Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eThe authors were careful to list the limitations of their work. First, the interventions and control groups across the included studies were not uniform. Some studies evaluated fruquintinib alone, while others tested it in combination with different chemotherapy drugs or immunotherapies. The control groups likewise varied, from placebo to active drugs like regorafenib or bevacizumab. This variety may have contributed to the statistical heterogeneity observed.\u003c\/p\u003e\n\n\u003cp\u003eSecond, there were variations in the definitions of progression-free survival used across studies, which may help explain the high heterogeneity (I² = 87%) seen for that outcome. Different ways of measuring when cancer progresses can yield different results.\u003c\/p\u003e\n\n\u003cp\u003eThird, the patient populations differed, especially in terms of tumor staging and the number of prior treatment lines. These differences may influence how effective fruquintinib is in any given individual.\u003c\/p\u003e\n\n\u003cp\u003eFourth, due to the limited number of studies, the analysis could not evaluate surgery-related outcomes. It also could not account for every possible clinical endpoint that matters to patients.\u003c\/p\u003e\n\n\u003cp\u003eFinally, several specific limitations bear emphasis:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall sample sizes\u003c\/strong\u003e in several component studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMissing data\u003c\/strong\u003e in some of the original publications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRegional bias\u003c\/strong\u003e — all studies were conducted exclusively in China, so the results may not fully apply to other ethnic groups, healthcare systems, or dietary and lifestyle contexts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor these reasons, the authors conclude that larger, multicenter, double-blind randomized controlled trials are needed to validate the findings. They note that their own study sought to consolidate existing evidence and depict overall trends and potential problems in fruquintinib use, rather than to provide a final, definitive safety verdict.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations from the Researchers\u003c\/h2\u003e\n\n\u003cp\u003eDespite the limitations, the researchers offered concrete, practical recommendations based on their analysis.\u003c\/p\u003e\n\n\u003cp\u003eGiven the observed odds ratio of 2.43 for hypertension and the fluctuation seen in sensitivity analysis, they recommend that \u003cstrong\u003ebaseline blood pressure and cardiovascular history be assessed before prescribing fruquintinib\u003c\/strong\u003e. High-risk patients — such as those with chronic kidney disease — should be monitored closely for blood pressure fluctuation. The authors go further: even for patients with a poor overall prognosis, weekly blood pressure monitoring is advised. If readings reach 140\/90 mmHg or above, antihypertensive treatment (blood pressure-lowering medication) should be started.\u003c\/p\u003e\n\n\u003cp\u003eManagement of high blood pressure that develops during treatment should follow the FRESCO-2 protocol:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eFor grade 3 hypertension (severe), suspend fruquintinib treatment until blood pressure improves to grade 1 (mild).\u003c\/li\u003e\n  \u003cli\u003eRestart treatment at a reduced dose of 4 mg, or if needed, 3 mg.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe researchers also advise avoiding combining fruquintinib with NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen) or other pressor drugs (medications that raise blood pressure), because these can compound the blood pressure effect. Patients should follow a low-salt diet and engage in regular exercise. The authors also call for research into biomarkers — for example, VEGF gene polymorphisms (natural variations in the gene) — that might predict which patients are most at risk of hypertension, enabling personalized dosing strategies.\u003c\/p\u003e\n\n\u003cp\u003eFrom a patient perspective, the key takeaways are straightforward:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFruquintinib offers a meaningful survival advantage in advanced colorectal cancer, with a roughly 31% lower risk of death and 56% lower risk of progression versus control treatments.\u003c\/li\u003e\n  \u003cli\u003eThe drug did not raise the overall rate of side effects or severe side effects in this analysis.\u003c\/li\u003e\n  \u003cli\u003eBlood pressure needs active monitoring during treatment, particularly in the first weeks and months, in line with the 21.6% rate of grade 3 hypertension seen in the FRESCO trial.\u003c\/li\u003e\n  \u003cli\u003eDiscuss any history of high blood pressure, kidney disease, or cardiovascular problems with your oncology team before starting fruquintinib.\u003c\/li\u003e\n  \u003cli\u003eDo not take NSAIDs or other blood-pressure-raising medications without checking with your doctor first.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe drug's short half-life (the time it takes for half the drug to be cleared from the body) and selective VEGFR inhibition may minimize off-target toxicity compared with less selective drugs like regorafenib — a theoretical advantage supported by the lower fatigue risk seen here. Fruquintinib continues to be investigated for earlier lines of treatment, and combination strategies with immunotherapy are a particularly active area of research.\u003c\/p\u003e\n\n\u003cp\u003eFour phase III trials now inform fruquintinib's evidence base. The combination of strong efficacy data from randomized trials and supportive real-world evidence from cohort studies makes these findings among the most comprehensive currently available on fruquintinib in Chinese colorectal cancer patients.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is fruquintinib and how does it work for colorectal cancer?\u003c\/h3\u003e\n\u003cp\u003eFruquintinib is an oral targeted cancer drug. It blocks vascular endothelial growth factor receptors, or VEGFRs, which tumors need to build new blood vessels. By interfering with this process, fruquintinib suppresses tumor growth. It is taken as a daily pill and is used mainly for advanced colorectal cancer that has not responded to earlier treatments.\u003c\/p\u003e\n\u003ch3\u003eWhat survival benefits did this analysis show for fruquintinib?\u003c\/h3\u003e\n\u003cp\u003eIn this analysis of 11 Chinese studies with over 2,300 patients, fruquintinib reduced the risk of death by about 31% and the risk of cancer progression or death by about 56%. Patients receiving fruquintinib lived longer without their cancer growing compared with patients who did not receive the drug.\u003c\/p\u003e\n\u003ch3\u003eIs fruquintinib approved for colorectal cancer?\u003c\/h3\u003e\n\u003cp\u003eYes. Fruquintinib was approved in China in 2018 for third-line treatment of metastatic colorectal cancer. In 2023, it was approved by the U.S. Food and Drug Administration for global use. Approval was based on pivotal trials that showed improved survival compared with placebo.\u003c\/p\u003e\n\u003ch3\u003eWhat are the common side effects of fruquintinib?\u003c\/h3\u003e\n\u003cp\u003eThis analysis found no overall increase in side effects or serious side effects compared with control treatments. However, there was a possible but unconfirmed link to high blood pressure. Fatigue risk was not significantly increased. Other side effects seen in trials include hand-foot syndrome, though this analysis did not specifically report that.\u003c\/p\u003e\n\u003ch3\u003eWhy is blood pressure monitoring important during fruquintinib treatment?\u003c\/h3\u003e\n\u003cp\u003eBecause high blood pressure is a known possible side effect of fruquintinib. In this analysis, the link was borderline and not confirmed, but sensitivity tests showed instability. In one large trial, about one in five patients on fruquintinib developed severe high blood pressure. Experts recommend weekly blood pressure checks during treatment.\u003c\/p\u003e\n\u003ch3\u003eWhat should I discuss with my doctor before starting fruquintinib?\u003c\/h3\u003e\n\u003cp\u003eTell your oncology team about any history of high blood pressure, kidney disease, or cardiovascular problems. Also discuss all medications you take, especially non-steroidal anti-inflammatory drugs like ibuprofen, which can raise blood pressure. Your doctor should assess your baseline blood pressure before prescribing fruquintinib.\u003c\/p\u003e\n\u003ch3\u003eAre the results of this analysis considered final?\u003c\/h3\u003e\n\u003cp\u003eNo. The authors stress that larger, more rigorous trials are still needed. All studies were conducted only in China, and treatment regimens varied widely. The analysis also noted potential differences in how cancer progression was measured. So while results are encouraging, they are not definitive for all patient groups.\u003c\/p\u003e\n\u003ch3\u003eFor advanced colorectal cancer that has stopped responding to earlier treatments, should I get a second opinion before starting fruquintinib?\u003c\/h3\u003e\n\u003cp\u003eFruquintinib has been shown in a meta-analysis of 11 Chinese studies to improve survival in advanced colorectal cancer, but the evidence is not definitive. The possible link to high blood pressure is real but unconfirmed, and larger trials are still needed. A second opinion can help you decide whether fruquintinib is appropriate after multiple prior therapies, especially if you have a history of high blood pressure or kidney disease. It can also clarify how to monitor blood pressure during treatment. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Efficacy and safety of fruquintinib in the treatment of colorectal cancer: a systematic review and meta-analysis of studies in China.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Feng Y, Shu Y.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Frontiers in Pharmacology, volume 16, article 1590782.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication dates:\u003c\/strong\u003e Received 10 March 2025; Accepted 13 August 2025; Published 09 September 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3389\/fphar.2025.1590782\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSystematic review registration:\u003c\/strong\u003e PROSPERO CRD420251002004 (https:\/\/www.crd.york.ac.uk\/PROSPERO\/).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding\/access note:\u003c\/strong\u003e This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for informational purposes and does not constitute medical advice. Patients should discuss all treatment options, including the benefits and risks of fruquintinib, with their oncology care team.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47560942157980,"sku":null,"price":0.0,"currency_code":"RUB","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ru\/products\/fruquintinib-for-colorectal-cancer-what-the-latest-evidence-shows-about-survival-and-side-effects","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}